in London, UK. The goal of the meeting was to provide researchers and physicians with an update of recent advances into early disease identification and treatment strategies of a range of gestational diseases. A selection of plenary addresses of interest is presented here.
The Gestational Diseases and Disorders in Pregnancy: Prevention, Identification, Treatment and Control conference, part of the 2013 Pregnancy Summit, was held on the 18th October 2013 in London, UK. The goal of the meeting was to provide researchers and physicians with an update of recent advances into early disease identification and treatment strategies of a range of gestational diseases. A selection of plenary addresses of interest is presented here.
Aberrations in both maternal and fetal cortisol homeostasis are associated with a range of adverse pregnancy outcomes, including preterm labor, stillbirth and fetal growth restriction. Recently, adult predisposition to a range of psychiatric disorders, including anxiety, has been linked to changes in fetal cortisol exposure in utero as the fetal limbic and neuroendocrine systems are, in part, regulated by cortisol. Ray Iles from Eric Leonard Kruse Foundation for Health Research (Glasgow, UK) and MAP Diagnostics in the UK presented data showing a correlation between maternal cortisol levels (assayed over several time points in a 24-hour period) and emotional health and stress levels in pregnancy. His next research question is to discern how changes in maternal cortisol affect fetal neurodevelopment and future predisposition to psychiatric disorders.
The use of selective genotyping and phenotyping strategies to achieve accurate patient profiling presents clinicians with the advantage of timely introduction of individualized preventative measures to reduce morbidity and mortality associated with most chronic diseases. Pregnancy is an opportune time to predict which diseases our patients are likely to be susceptible to as the often profound but 'normal' gestational and physiological changes could unmask a 'latent' maternal predisposition to chronic diseases, including hypertension, diabetes and depression.
David Williams from the University College London (UK) outlined a compelling paradigm demonstrating how pregnancy can act as a stressor agent to unmask a latent maternal predisposition to a range of chronic diseases, including diabetes, thyroid disease, hypertension and some autoimmune conditions. He presented some preliminary results showing a direct correlation between gestational diabetes and preeclampsia and the onset of adult type diabetes and cardiovascular disease, including cerebrovascular disease and venous thromboembolism. A pregnant woman who succumbs to gestational diabetes or severe preeclampsia increases their lifetime risk of developing diabetes or chronic hypertension by up to 50% and 30%, respectively. Women who develop gestational diabetes have up to an eightfold increased risk of Type 2 diabetes, with this risk further modified by early gestation of onset, use of insulin in pregnancy and a marked increased in maternal weight gain during pregnancy. The gestation of onset and severity of the pregnancy disease syndrome appear to correlate with risk and severity of adult disease: for instance, early preterm (less than 34 weeks) preeclampsia is associated with a staggering (2014) 10(5) future science group Conference Scene Lartey sevenfold increase in adult chronic hypertension. Pregnancy is also a time of latent susceptibility when autoantibodies associated with certain autoimmune diseases, including systemic lupus erythematosus and autoimmune thyroid disease, can be detected before the later onset of the clinical adult disease syndrome.
Womens Health
The 'fetal syndrome' of disease is also providing further insights into the phenotype of both paternal and maternal adult disease. Preeclampsia with intrauterine growth restriction is associated with an increase in both maternal renal disease and chronic hypertension. Men who father a growth-restricted fetus are more likely to become insulin resistant in later life. Crucially the extent of insulin resistance can be predicted by extent of intrauterine growth restriction.
Thus the postpregnancy review by the obstetrician and primary care physician represents an often-missed opportunity to institute lifestyle changes and medical treatment to improve clinical outcomes across the board in these conditions. Measures such as aspirin and ACE inhibitors after preeclampsia or oral hypoglycemic agents can be instituted after a woman's family is complete. More research will be required to assess the effect of these measures.
We are now gaining new insights into how severe dietary manipulation can alter the clinical phenotype and outcome in patients with Type 2 diabetes. A small study in Newcastle University (UK) has outlined some remarkable results, with a complete reversal of disease phenotype in isolated cases. Fetal macrosomia is a side effect of poorly controlled diabetes. Marianne Vestgaard from Herning Hospital in Denmark presented impressive preliminary data showing how dietary manipulation can limit excessive fetal weight gain in women with gestational diabetes. A larger scale study will hopefully report soon to confirm the results of this study.
Preeclampsia and other hypertensive disorders of pregnancy are implicated in a third of all cases of severe maternal morbidity and remain important causes of maternal death worldwide. They also cause high levels of fetal morbidity and mortality and are associated with intrauterine growth restriction, stillbirth and preterm labor. One of the problems encountered in the management of preeclampsia is the lack of a reliable biomarker that can be used in accurate patient profiling, diagnosis and the prediction of disease severity prediction. Prof. Hromadnikova's group from the Charles University in Prague (Czech Republic) have made novel breakthroughs in profiling patients with hypertensive diseases in pregnancies using microRNA expression analysis. The authors of this paper presented data showing changes in the expression of several chromosome 19 microRNAs in placental samples from pregnancies affected by preeclampsia and intrauterine growth restriction. They reported an upregulation of several chromosome 19 microRNAs (miR517, miR520a and miR-525) in affected pregnancies. These changes were not reflected in plasma assays, limiting its potential as the 'elusive' magic biomarker agent for preeclampsia.
Michael Lechner from the Paracelsus Medical University, Salzburg, Austria, presented results obtained using a new diagnostic algorithm, which has led to a reduction in the need for surgical exploration and repair, in the management of inguinal herniae in pregnancy. The new protocol utilizing color Doppler sonography and a multidisciplinary clinical diagnostic approach has led to improvements in detection of positive cases and raised the threshold required for intervention. They have successfully used the protocol to conservatively manage 18 patients who presented at various stages in pregnancy. This approach using specialized radiological imaging and clinical intervention may be extrapolated to provide equally impressive outcomes for other surgical complications in pregnancy.
Nita Solanky from Institute of Child Health, University College London presented progress on the Wellbeing of Women-funded BabyBank tissue bank. This unique resource aims to collect plasma, serum, urine and DNA samples from women and their partners from pregnancies complicated by recurrent miscarriage, preeclampsia, intrauterine growth restriction and preterm delivery. The tissue bank is a valuable resource that will hopefully alleviate the problem of scarcity of samples, which very often hinders research in this area. The Babybank tissue bank welcomes applications from other noncommercial and commercial institutions and access to this resource is via on online application.
Normal maternal thyroid homeostasis is crucial for optimal neurological development of the fetus. As well as low IQ, neurodevelopmental delay and behavioral problems, mild thyroid hormone insufficiency in pregnancy has also been linked to other adverse obstetric outcomes including stillbirth, placental abruption, preeclampsia, intrauterine growth restriction and gestational diabetes. Bijay Vaidya from the Royal Devon & Exeter Hospital & University of Exeter Medical School (UK), outlined a synopsis of the current evidence for screening for subclinical thyroid disease in pregnancy and the rationale for a new research proposal to clarify which at risk groups' merit screening. He also proposed the implementation of different test thresholds and measures of evaluating outcome in these groups. Controversies currently exist regarding the possible impact that selective and universal screening for subclinical thyroid disorders may have on obstetric outcomes. Although targeted screening may miss up to a third of women with hypothyroidism, there is no evidence from future science group Conference scene report for the Gestational Diseases Conference in London Conference Scene randomized controlled trials of improved maternal and fetal outcomes in treated case-positive patients from either universal screen or family or personal historyindicated patients. This is further confounded by the fact that there is no evidence that thyroxine supplementation in mild hypothyroidism improves pregnancy outcomes. New research should clarify the issues above.
The 'new kid on the block' in prenatal diagnosis of chromosomal abnormalities is free fetal DNA in maternal plasma or non-invasive prenatal testing (NIPT). With problems with mosaicism and the ever present risk of miscarriage associated with chorionic villus sampling or amniocentesis, NIPT heralds a new age of 'risk-free' prenatal diagnosis for patients and their families, promising improvements in fetal sex determination, detection of fetal aneuploidies T21, 18 and 13 and in the management of rhesus isoimmunization. Current problems limiting the appeal of NIPT include low free fetal DNA yields due to problems with sample purification and relatively high background levels of maternal DNA levels in plasma, a high-test rejection rate and an expensive £600 prize tag. Maiwenn Kersaudy-Kerhoas from Heriot Watt University (Edinburgh, UK) presented preliminary data on a new technique of blood plasma sample isolation on a microfluidic chip, which has several potential advantages over the standard centrifugation isolation preparation. These include better quality and higher relative fetal DNA yields, more efficient housekeeping gene amplification and hopefully more accurate detection of aneuploidy related chromosomal anomalies and fetal sexing. Watch this space! Euroscicon's Pre-Eclampsia Summit will take place in April 2015 [1] .
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